Erzincan Merkez

Intertrochanteric femur fractures frequently affect elderly patients and cause significant pain, especially during positioning for spinal anesthesia and after surgery. Researchers are comparing two regional anesthesia techniquesthe Pericapsular Nerve Group PENG block and the Deep Iliacus Plane Block DIPBto see which provides better pain relief with fewer side effects in patients undergoing surgery for these fractures. This study is a prospective, randomized controlled trial conducted to address the lack of data comparing these two approaches.

Periodontitis, a common gum disease worldwide, is being studied to explore the role of a protein called Mitofusin-1 Mfn1 found in saliva. Researchers aim to understand how Mfn1 relates to the severity of periodontitis, including in smokers, and how it changes with treatment. The study includes people with healthy gums, mild to severe periodontitis, and smokers with severe periodontitis to assess the potential of Mfn1 as a diagnostic and monitoring marker. Participants are divided into four groups based on gum health and smoking status healthy individuals, those with mild periodontitis, severe periodontitis, and severe periodontitis with regular smoking. All participants provide saliva samples and undergo clinical gum exams. People with periodontitis receive standard non-surgical periodontal therapy, which removes plaque and smooths tooth roots to help gum healing. The study measures Mfn1 in saliva at the start and three months after treatment. During the study, participants provide saliva samples and receive thorough gum examinations to track disease severity and response to treatment. Researchers also analyze other saliva components related to gum health. The main outcome is the Mfn1 protein level at the beginning, with follow-up measurements after therapy. The study lasts at least three months post-treatment, with ongoing assessments of gum health and saliva markers to understand Mfn1s role in periodontitis diagnosis and follow-up.

Postoperative pain after total knee arthroplasty TKA can delay recovery, lower patient satisfaction, and increase the need for pain medicine. Researchers are studying three nerve block techniquessciatic nerve block, Biceps Femoris Short Head BiFeS block, and Interspace Between the Popliteal Artery and the Capsule of the posterior Knee IPACK blockto see which works best when added to the commonly used adductor canal block. The goal is to find the optimal combination to control pain while preserving leg movement and improving patient satisfaction. This research is a prospective, double-blind, randomized controlled trial including at least 102 adults aged 18 to 75 scheduled for elective unilateral primary TKA. Patients are randomly assigned to receive one of three combinations adductor canal block plus sciatic nerve block, adductor canal block plus BiFeS block, or adductor canal block plus IPACK block. All nerve blocks use ultrasound guidance and a mixture of local anesthetics. Surgery is performed under spinal anesthesia, and all blocks are done by an experienced anesthesiologist. Participants will be closely monitored during and after surgery. Pain levels will be measured using a visual analog scale at several points within 24 hours postoperatively. Motor function, opioid use, and patient recovery quality will also be assessed. Standard pain medications are given, with tramadol as rescue medication if needed. Data collectors and outcome assessors remain blinded to the treatment groups. The study will run over a 12-month period starting November 2025.

Researchers are evaluating the safety and performance of the Occlutech Atrial Flow Regulator device in patients with heart failure. This international, multicenter follow-up registry aims to identify unknown side effects and determine when this treatment is appropriate. The study focuses on patients with chronic symptomatic heart failure and monitors outcomes over a 36-month period after device implantation. Participants will receive the Occlutech Atrial Flow Regulator, which is an interatrial shunt device delivered through a catheter. Treatments and procedures follow clinical routine and device instructions, performed by experienced physicians at equipped centers. The study tracks device performance and cardiovascular events at 12, 24, and 36 months after implantation. During the study, participants will undergo assessments including vital signs, lab tests, quality of life questionnaires, ECGs, and echocardiograms. Researchers will measure major adverse cardiovascular and neurological events within one year, as well as heart function, exercise capacity, and medication changes over three years. Safety and efficacy will be closely monitored throughout the follow-up period.